Abstract :
The allosteric inhibitor asciminib was active in 150 heavily pretreated patients with Philadelphia chromosome-positive chronic myeloid leukemia who had resistance to or unacceptable side effects from tyrosine kinase inhibitors. These patients include those whom ponatinib had failed and those with a T315I mutation. Low-grade reversible toxic effects occurred in a minority of patients.